FDA Expands Ferric Maltol Approval to Adolescents for Iron Deficiency Treatment
核心洞察
The FDA has approved an expanded indication for ferric maltol (ACCRUFeR) to include pediatric patients aged 10 years and older with iron deficiency (搜索), following a priority review.
The approval was supported by Phase 3 clinical trial data showing a clinically meaningful average hemoglobin increase of 1.1 g/dL at Week 12 in adolescent patients.
This non-salt-based oral iron therapy addresses significant tolerability issues associated with traditional iron salts that often lead to poor patient compliance in pediatric populations.
The FDA has approved an expanded indication for ferric maltol (ACCRUFeR; Shield Therapeutics (搜索)), extending use of the oral iron therapy to include pediatric patients aged 10 years and older with iron deficiency (搜索), following a priority review. The decision broadens access beyond adults, for whom the therapy was first approved in 2019, and reflects growing clinical evidence supporting the safety and efficacy of ferric maltol in younger populations with iron deficiency and iron deficiency anemia (搜索).
Clinical Evidence Supporting Pediatric Use
The FDA's approval for pediatric patients aged 10 to 17 years was supported by efficacy data from the FORTIS clinical trial, which evaluated ferric maltol in adolescents with iron deficiency (搜索). In that study, 24 pediatric patients received age-based dosing of ferric maltol capsules twice daily. Treatment resulted in a clinically meaningful average increase in hemoglobin of 1.1 g/dL at Week 12, an improvement the agency noted is comparable, on average, to the hemoglobin increase typically seen after a single blood transfusion.
Additional pediatric evidence came from the broader Phase 3 FORTIS/ST10-01-305 program, which included children from 1 month to 17 years of age with mild to moderate iron deficiency anemia (搜索). In that open-label, randomized study, children aged 2 to 17 years were randomized to receive either ferric maltol or ferrous sulphate, while infants younger than 2 years all received ferric maltol. According to Shield Therapeutics (搜索), the trial confirmed efficacy and tolerability and represents the final study in a comprehensive pediatric development program committed to both US and European regulators.
Addressing Unmet Medical Needs in Adolescents
Iron deficiency (搜索) is among the most common nutritional and hematologic conditions worldwide and can affect patients across a wide range of ages and clinical settings. In pediatric patients, untreated iron deficiency and iron deficiency anemia (搜索) may contribute to fatigue, impaired cognitive development, and reduced physical endurance. According to the World Health Organization, roughly half of all anemia (搜索) cases globally are caused by iron deficiency.
Iron deficiency (搜索) remains the most common nutrient deficiency in the world, serving as a major public health hurdle. Although it is most prevalent in infants, the second most common peak occurs during adolescence, driven by the high physiological demands of rapid growth and, in girls, the onset of menstrual bleeding. For children and teenagers, iron deficiency can interfere with neurodevelopment, myelination, and neurotransmission. In adolescents, this often manifests as decreased cognitive function, lower academic success, irritability, and difficulty in understanding or perception.
Improved Tolerability Profile
Until now, the standard of care for pediatric iron deficiency (搜索) primarily involved oral iron salts, such as ferrous sulfate or ferrous fumarate. Although effective, these treatments are notorious for adverse effects that lead to poor patient compliance. Families often report that children suffer from nausea, vomiting, dyspepsia, and a lingering bad taste, alongside the physical discoloration of teeth and stool.
Ferric maltol is a non-salt-based oral iron therapy designed to improve gastrointestinal tolerability compared with traditional iron salts. Shield Therapeutics (搜索) has described the drug as having a novel mechanism of absorption, which may allow for more predictable restoration of iron levels while minimizing gastrointestinal adverse effects associated with conventional oral iron products.
Safety Profile and Contraindications
According to the FDA, ferric maltol should not be used in patients with known hypersensitivity to the product or its excipients, those with hemochromatosis (搜索) or other iron overload syndromes, or patients receiving repeated blood transfusions. The agency also advises avoiding ferric maltol during inflammatory bowel disease (搜索) flares and highlights the risk of iron overload. The most common adverse reactions reported include flatulence, diarrhea, constipation, discolored feces, abdominal pain, nausea, vomiting, and abdominal discomfort or distension.
Future Development Plans
Shield Therapeutics (搜索) announced plans to seek a further indication expansion to include children as young as 1 month of age, alongside submission of a new drug application for a pediatric suspension formulation used in their Phase 3 study. "Shield plans to file for a further extension of the indication to include children 1 month and above in conjunction with the submission of an NDA for a new pediatric formulation (ferric maltol suspension), which was used in the successful FORTIS Phase 3 study in this population. If approved, this formulation may also offer an alternative approach for adults who can't swallow our current capsule formulation," the company stated.
The expanded pediatric approval addresses a substantial unmet need, particularly for adolescents who may experience iron deficiency (搜索) related to growth, dietary factors, or blood loss. Shield Therapeutics (搜索) estimates that iron deficiency and iron deficiency anemia (搜索) affect approximately 20 million people in the United States, representing a significant clinical and economic burden.